FRESCO2 Study: FDA Approval of Fruquintinib for Refractory Colorectal Cancer

Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients.

Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice.

Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com